AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03184233 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: No rapid ventricular pacing
Description: No rapid ventricular pacing is applied perioperatively.
Study NCT03374436 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High-Carbohydrate Active
Description: Three high-carbohydrate meals will be consumed (breakfast, lunch, and dinner) at \~3 hour intervals while participants remain in a seated position for the entire 9 hour intervention period except that once every hour they will ascend three flights of stairs vigorously (stair climbing sprint snack) for a total of 8 active breaks.
Study NCT01038440 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: SDA
Description: Four different doses of SDA (0.5, 1.5, 3.0 and 6.0 g/d) consumed with food daily.Subjects consuming more than 1 softgel/day (as in the groups with 1.5 and 3.0 g/d) are instructed to consume the softgels in 2 or 3 separate servings.
Study NCT01367665 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vismodegib
Description: 150 mg once daily until disease progression or unacceptable toxicity
Study NCT05783544 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Interleukin-1B
Description: Level of serum interleukin-1B will be detected
Study NCT05783544 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Interleukin-4
Description: Level of serum interleukin-4 will be detected
Study NCT05783544 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Interleukin-6
Description: Level of serum interleukin-4 will be detected
Study NCT05783544 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: tumor necrosis factor - a
Description: Level of serum tumor necrosis factor - a will be detected
Study NCT05783544 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: interferon- gamma
Description: Level of serum interferon- gamma will be detected
Study NCT02497651 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Liquid mixed meal
Description: The subjects will ingest a 400 ml chocolate drink, rich on carbohydrates, fat and lipids. In the following 4 hours, blood samples will be drawn from a PVC for the measurement of plasma glucose, gut- and pancreatic hormones, acetaminophen etc. After the 4 hours, the subjects will be offered an ad libitum meal.
Study NCT03374436 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Low-carbohydrate Sedentary
Description: Three low-carbohydrate meals will be consumed (breakfast, lunch, and dinner) at \~3 hour intervals while participants remain in a seated position for the entire 9 hour intervention period. This condition will provide a condition where the blood glucose and insulin responses are relatively low and stable throughout the day.
Study NCT01503619 — intervention group
Intervention type: OTHER
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT00675662 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention
Description: Lifestyle intervention with Trim Tots pre-school programme.
Study NCT00675662 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: waiting list control
Description: waiting list control
Study NCT02244008 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: joint mobilization
Description: The experimental group received joint mobilization (anteroposterior mobilization of the talus - Maitland grade III). During the mobilization cyclic movements were applied in an anteroposterior direction from the first tissue resistance barrier until the end of the accessory range of motion without any pain or discomfort. This mobilization maneuver was performed in 30-second duration sets with a 30-second interval between each set. The interventions lasted two weeks with three sessions each, completing six sessions.
Study NCT02244008 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: manual contact
Description: The placebo group received only manual contact. This maneuver was performed in 30-second duration sets with a 30-second interval between each set. The interventions lasted two weeks with three sessions each, completing six sessions.
Study NCT03674541 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pyridostigmine Bromide
Description: Pyridostigmine Bromide 60 mg capsule by mouth as a one time dose
Study NCT03674541 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (Cellulose microcrystalline) capsule by mouth as a one time dose
Study NCT02580591 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin
Study NCT02580591 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: For blinding purposes
Study NCT02580591 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: For blinding purposes
Study NCT03336060 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Cortical Correlates of Jump Landing Task
Description: The study participants perform counter-movement jumps (CMJ, flight time approximately 500 ms) followed by single leg landings. While under an anticipated condition, the individuals receive the visual information (presented on a screen) on which leg/ foot (left, right) they are required to land before self-initiated CMJs, the individuals will receive this information under the non-anticipated condition only after take-off (approximately 400 ms before ground contact).
Study NCT02283541 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Automatic self-transcending meditation
Description: ASTM is a category of meditation that helps quiet the mind and induce physiological and mental relaxation while the eyes are shut. It utilizes relaxed attention to a specific sound value (mantra) according to specific criteria, in order to draw attention inward.
Study NCT01785498 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Supplementary resources
Description: Clinical and educational resources for patients, their families and the professionals who care for them.
Study NCT03793634 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: topical chamomile
Description: herbal medication which has antioxidant, anti-inflammatory and anticarcinogenesis effect
Study NCT03793634 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: topical chamomile
Description: herbal medication which has antioxidant, anti-inflammatory and anticarcinogenesis effect
Study NCT02978170 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cone-Beam Computed Tomography
Description: Undergo CBCT
Study NCT03704389 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Clinical decision support
Description: Clinical decision support nudges within the electronic health record
Study NCT02451189 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Inulin acetate ester
Description: Inulin acetate ester supplementation (10g/d) for 30 days. Appetite measurements on day 15 and oral glucose tolerance test (OGTT) on day 30.
Study NCT02451189 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Inulin propionate ester
Description: Inulin propionate ester supplementation (10g/d) for 30 days. Appetite measurements on day 15 and OGTT on day 30.
Study NCT02451189 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Inulin butyrate ester
Description: Inulin butyrate ester supplementation (10g/d) for 30 days. Appetite measurements on day 15 and OGTT on day 30.
Study NCT00863941 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abrika Bupropion 150 mg XL Tablet, single dose
Description: A: Experimental Subjects received Abrika formulated products under fasting conditions
Study NCT00863941 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Wellbutrin XL® 150 mg Tablet, single dose
Description: B: Active comparator Subjects received GlaxoSmithKline formulated products under fasting conditions
Study NCT04090697 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxandrolone
Description: Oxandrolone 2.5mg tabs will be suspended in multi-chain triglyceride (MCT) oil and administered buccally.
Study NCT01301755 — intervention group
Intervention type: PROCEDURE
Intervention: Lung aspiration
Description: direct lung tissue Aspergillus galactomannan antigen detection from aspirate by ultrasound-guided fine needle aspiration
Study NCT03411434 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylphenidate Oral Tablet
Description: cf arm group description
Study NCT04884906 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Camrelizumab
Description: 200mg/m2, iv, d1, Q3W, a total of 6 cycles
Study NCT04884906 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiotherapy
Description: 1.8-2.15Gy/time (radiotherapy started on the 8th day of camrelizumab treatment), a total of 28 times (5 times a week), a total of 50.4-60.2Gy.
Study NCT04884906 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albumin Paclitaxel
Description: 260mg/m2, iv, d1, Q3W, a total of 6 cycles
Study NCT04884906 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 80-120mg/m2, iv, d1-3, Q3W, a total of 6 cycles
Study NCT02562976 — intervention group
Intervention type: OTHER
Intervention: gastric atrophy and intestinal metaplasia
Description: use Japanese endoscopic gastric atrophy classification, Operative Link on Gastritis Assessment (OLGA), Operative Link on Gastric Intestinal Metaplasia Assessment (OLGIM) to evaluate the severity of gastric atrophy and intestinal metaplasia
Study NCT01838304 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Probability ramp control
Description: Decision support software that calculates propofol doses appropriate for age and weight of the patient
Study NCT01838304 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Monitoring
Description: Manual recording of drug doses determined by CRNA
Study NCT03225560 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bowel Preparation
Description: Bowel Preparation is completed prior to colonoscopy to ensure adequate visualization of the bowel lumen. This requires diet modifications and taking of medications at specified time intervals.
Study NCT03225560 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Bowel Preparation
Description: Bowel Preparation is completed prior to colonoscopy to ensure adequate visualization of the bowel lumen. This requires diet modifications and taking of medications at specified time intervals.
Study NCT00925067 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: laparoscopic (TEP) inguinal hernia repair
Description: laparoscopic inguinal hernia repair with a standard heavyweight Marlex (control group) prosthesis or new generation lightweight VyproII and TiMesh prostheses (study group)
Study NCT00925067 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: lightweight TiMesh
Study NCT00925067 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: lightweight VyproII
Study NCT00925067 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Heavyweight Marlex
Study NCT01546090 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alprazolam
Description: preoperative administration of an orally 0.50 mg single dose
Study NCT01546090 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo capsules were filled with starch
Study NCT00595868 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Varenicline
Description: 0.5 milligrams two times per day for 3 days, then 1.0 milligrams two times per day for an addition 11 days - 2 months
Study NCT00595868 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: same as Varenicline arm
Study NCT00331084 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: antibiotic/steroid combination
Description: 1 gtt, 4x/day, 15 days
Study NCT00331084 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: moxifloxacin / dexamethasone
Description: 1 gtt 4x/day, 15 days
Study NCT02498327 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Gelatine Capsule
Description: Gelatine capsules containing only the inactive ingredients of starch amyral white, di-calcium phosphate DC and magnesium stearate fine.
Study NCT02498327 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Venavine Intensive®
Description: Gelatine capsules containing 360 mg Red Vine Leaf extract, 60 mg of Horse Chestnut extract, 35 mg of Butchers Broom extract and 3,2 mg of Vitamin B6 as well as the inactive ingredients of starch amyral white, di-calcium phosphate DC and magnesium stearate fine.
Study NCT02483065 — intervention group
Intervention type: OTHER
Intervention: mortality at discharge and 3-months after the admission in patients with and without dementia
Description: Patients diagnosed of dementia who ingresed the hospital were informed of the goals of the study and invited to voluntarily participate. In order to take part in the study, patients were required to provide informed consent. All participants were first screened with the Alzheimer's Disease Test. A diagnosis of dementia was generated by an independent clinician experienced in old age psychiatry using a structured clinical assessment based on operationalized DSM-IV criteria. Clinical data were gathered from hospital notes. Information on sociodemographic data, premorbid basic and instrumental activities of daily living, quality of life and burden of the caregiver was gathered from carers and review of hospital notes. In both cohorts, participants were telephoned 3 months after hospital admission to respond the follow-up questionnaires. Patients who decided not to answer them were considered lost to follow-up. All information was kept confidential.
Study NCT03108300 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propranolol Hydrochloride
Description: propranolol hydrochloride is a beta-adrenergic receptor blocker
Study NCT03108300 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Doxorubicin is a chemotherapy which will be injected by a dose 60 mg per meter square of body surface area to be repeated every 21days
Study NCT04072536 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electric wheelchair with activated assistance module
Description: This evaluation will be carried out in 3 standardized test circuits of increasing difficulty, one week apart. At each session, the patient will perform the circuit 6 times, including 3 with activated assistance
Study NCT04072536 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Electric wheelchair with assistance module not activated
Description: This evaluation will be carried out in 3 standardized test circuits of increasing difficulty, one week apart. At each session, the patient will perform the circuit 6 times, including 3 with no activated assistance
Study NCT01025232 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ranibizumab
Description: Intravitreal Injection of 2.0mg formulation
Study NCT02437968 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Camp Cope-A-Lot (Computer-assisted CBT program)
Description: Camp Cope-A-Lot is a computer-assisted program that includes psychoeducation and clinician guided exposure tasks for anxious children.
Study NCT02282891 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Induction of general anesthesia using propofol 2mg/kg
Study NCT02497651 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Skin Biopsy
Description: All subjects will undergo a skin biopsy procedure. Two small (3 mm) biopsies will be taken from the hip area under local anaesthesia. Standard wound treatment will follow.
Study NCT02242916 — intervention group
Intervention type: RADIATION
Intervention: Photon therapy versus proton therapy
Study NCT02242916 — intervention group
Intervention type: RADIATION
Intervention: Photon therapy versus C-ion therapy
Study NCT00668161 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: 60 minutes/session of aerobic exercise, 6 d/week at 50-50% HHR. All sessions will begin with 10 minutes of stretching and 5 minutes of warm-up, and will end with 5 minutes of cool down.
Study NCT02066103 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Study NCT00077857 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine (Xeloda®)
Description: 825 mg/m\^2 or 1250 mg/m2 orally twice a day on days 1 to 14 of each 3 week cycle.
Study NCT00077857 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel (Taxotere®)
Description: 75 mg/m\^2 intravenous on day 1 of each 3 week cycle
Study NCT03732235 — intervention group
Intervention type: DEVICE
Intervention: TACE+ systemic Bevacizumab
Description: PEG embolics
Study NCT02282891 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol-Ketamine
Description: Induction of general anesthesia using a mixture of 1.5 mg/kg:0.75 mg/kg propofol/ketamine
Study NCT02103595 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Accu-Chek FlexLink
Description: Insulin pump device used for 4-weeks under real life conditions
Study NCT02103595 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Accu-Chek FlexLink Plus
Description: Insulin pump device used for 4-weeks under real life conditions
Study NCT03732235 — intervention group
Intervention type: DRUG
Intervention: FOLFIRI+Bevacizumab
Description: antiangiogenic factor
Study NCT03732235 — intervention group
Intervention type: DEVICE
Intervention: TACE
Description: PEG embolics
Study NCT04223206 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: NATURLENS
Description: Oral administration of dietary supplement (26 g/day) to dissolve in 100 or 150 mL of water
Study NCT00540527 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: local interarterial recombinant tissue plasminogen activator
Description: Endovascular treatment must be performed asap after random.and definitely within 6h from symp. onset.It includes intrarterial thrombolysis with rt-PA,if necessary,associated to or substituted by mechanical clot disruption and/or retrieval.Fibrinolytic therapy should be performed within 1h,the full dose of rt-PA infusion should not exceed 0.9 mg/kg (max 90 mg in the case of body weight ≥100 kg).If a complete recanalization is achieved,rt-PA infusion can be interrupted before reaching the maximum dosage.The option of performing a thrombolysis by mechanical means to obtain a mechanical disintegration/shift/detach/fissure of the thrombus and/or a retraction/aspiration can be considered on the basis of the type,location and characteristics of the occlusion.These choices may involve the use of the microguidewire as a mechanical instrument to favour the disintegration of the thrombus,using systems to capture the thrombus by extraction or more complex systems to crush and aspirate the thrombus
Study NCT00540527 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: intravenous (IV) rt-PA
Description: IV thrombolytic treatment is started immediately after randomization, within 4.5 h of symptoms onset. IV rt-PA is administered at a dose of 0.9 mg/kg (max 90 mg), 10% of which is given as a bolus, followed by the delivery of the remaining 90% as a constant infusion over 60 mins
Study NCT04437316 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Use of Low level Laser after wisdom tooth removal
Description: Directly after the wisdom teeth removal of the right/left side, one of the low level laser (therapeutic and non-therapeutic (Placebo)) is used.
Study NCT04437316 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Use of Low level Laser after wisdom tooth removal
Description: Directly after the wisdom teeth removal of the right/left side, one of the low level laser (therapeutic and non-therapeutic (Placebo)) is used.
Study NCT01301404 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 10% carbohydrate drink
Description: In the study group, 10% carbohydrate drink 400 ml will be given between 18-24 hr the night before surgery and another 400 ml will be drunk at 6-7 hr in the morning of surgery.
Study NCT04130100 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Low Dose of Mesenchymal stem cell
Description: Mesenchymal stem cell injection
Study NCT04130100 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: High Dose of Mesenchymal stem cell
Description: Mesenchymal stem cell injection
Study NCT04130100 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium Hyaluronate
Description: Sodium Hyaluronate injection
Study NCT01801124 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EXPAREL
Description: single dose 266 mg of undiluted EXPAREL
Study NCT00850265 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Volumatic spacer
Description: A spacer is a plastic device to inhaler medication
Study NCT04434261 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: PT-PCR test for SARS-CoV-2
Description: Screening test for the diagnosis of SARS-CoV-2 in asymptomatic patients
Study NCT04416984 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: ALLO-501A
Description: ALLO-501A is an allogeneic CAR T cell therapy targeting CD19
Study NCT04416984 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ALLO-647
Description: ALLO-647 is a monoclonal antibody that recognizes a CD52 antigen
Study NCT04416984 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Chemotherapy for lymphodepletion
Study NCT04416984 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Chemotherapy for lymphodepletion